
(IN BRIEF) Boehringer Ingelheim, via its subsidiary NBE Therapeutics, has launched a cutting-edge ADC research and development facility in Basel with a CHF 27 million investment. The center is a key part of the company’s strategic efforts to advance next-generation … Read the full press release